Emerging molecular biomarkers for early diagnosis of human diseases

The initial detection of human diseases remains a critical cause of therapeutic ability and patient survival, therefore involving the development of sensitive and specific molecular biomarkers. Additional diagnostic approaches are limited by low sensitivity, delayed detection, and invasive procedures, underscoring the need for innovative molecular strategies. This mini review aims to evaluate emerging molecular biomarkers and their potential use in the initial diagnosis of major human diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions.

Current advances in high-throughput omics technologies encompassing genomics, transcriptomics, proteomics, and metabolomics have facilitated the recognition of diverse biomarker. Circulating biomarkers such as cell-free DNA (cfDNA), microRNAs (miRNAs), extracellular vesicles, and disease-specific protein signatures have reveal significant promise due to their minimally invasive nature and high diagnostic accuracy. Additionally, integrative multi-omics approaches combined with artificial intelligence-driven analytical models have increased biomarker discovery, validation, and predictive performance.

Despite these advancements, several limitations force their clinical translation. These involves the lack of standardized protocols for sample collection and analysis, variabilityacross populations, limited large-scale validation studies, and challenges related to cost-effectiveness and regulatory approval. Additionally, the heterogeneity of diseases and biomarker expression profiles complicates their universal applicability.

The emerging molecular biomarkers represent a transformative approach for initial disease detection and precision medicine. However, addressing existing methodological and translational challenges through rigorous validation and standardization is essential to facilitate their integration into routine clinical practice and better healthcare outcomes.